XBI Fair Value: Look-Through Valuation
Equity Rank publishes model fair values for holdings making up 39% of XBI, too little for a fund-level model figure (the threshold is 60%). Data as of 2026-10-22. Net assets $10.4B; holdings as of 2026-10-22.
Top 25 holdings of 163
| Holding | Weight | Price | Model fair value | Gap |
|---|---|---|---|---|
| MRNA Moderna Inc | 2.57% | — | Not covered | — |
| NTRA Natera Inc | 1.84% | $401.37 | $343.38 | -14.4% |
| TWST Twist Bioscience Corp | 1.82% | — | Not covered | — |
| ABBV AbbVie Inc | 1.74% | $285.19 | $231.45 | -18.8% |
| BIIB Biogen Inc | 1.70% | $253.84 | $220.75 | -13.0% |
| AMGN Amgen Inc | 1.68% | $447.28 | $446.49 | -0.2% |
| HALO Halozyme Therapeutics Inc | 1.68% | $124.54 | $84.01 | -32.5% |
| IOVA Iovance Biotherapeutics Inc | 1.67% | — | Not covered | — |
| UTHR United Therapeutics Corporation | 1.64% | $584.79 | $468.65 | -19.9% |
| GILD Gilead Sciences Inc | 1.63% | $157.19 | $146.56 | -6.8% |
| EXEL Exelixis Inc | 1.61% | $65.31 | $76.32 | +16.9% |
| TGTX TG Therapeutics Inc | 1.53% | $53.16 | $52.59 | -1.1% |
| REGN Regeneron Pharmaceuticals Inc | 1.49% | $819.09 | $1024.52 | +25.1% |
| VRTX Vertex Pharmaceuticals Inc | 1.48% | $535.17 | $492.46 | -8.0% |
| KRYS Krystal Biotech Inc | 1.47% | $320.13 | $202.30 | -36.8% |
| RVMD Revolution Medicines Inc | 1.44% | — | Not covered | — |
| PTGX Protagonist Therapeutics Inc | 1.44% | $139.53 | $122.42 | -12.3% |
| GRAL GRAIL, LLC | 1.43% | — | Not covered | — |
| CRSP Crispr Therapeutics AG | 1.42% | — | Not covered | — |
| SYRE Spyre Therapeutics Inc. | 1.40% | — | Not covered | — |
| PCVX Vaxcyte Inc | 1.40% | — | Not covered | — |
| INCY Incyte Corporation | 1.37% | $116.93 | $194.25 | +66.1% |
| PTCT PTC Therapeutics Inc | 1.36% | — | Not covered | — |
| NBIX Neurocrine Biosciences Inc | 1.35% | $143.29 | $132.60 | -7.5% |
| ALNY Alnylam Pharmaceuticals Inc | 1.34% | $227.28 | $220.56 | -3.0% |
Related
GDX · IBB · IGV · ITA · ITB · JETS · KBE · KRE · All ETFs · Stocks by industry